GlassScriptPhysician profile
Yomi Clement
NPI 1356005789
$3,048.66
in general payments reported to CMS, 2019-2025
21 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,270 · 2023: $1,483 · 2024: $149 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.10 |
| Education | $465.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $512.25 | 2022-2025 | |
| Seagen INC. | $451.83 | 2022-2023 | |
| Sobi, INC | $413.19 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $249.18 | 2022-2023 | Opdivo |
| Gilead Sciences, INC. | $238.55 | 2022-2023 | Trodelvy |
| Glaxosmithkline, LLC. | $221.75 | 2022-2023 | Shingrix |
| Incyte Corporation | $184.94 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $110.47 | 2022-2023 | Padcev |
| Genzyme Corporation | $83.38 | 2022-2023 | |
| Janssen Biotech, INC. | $70.75 | 2022-2023 | Imbruvica |
| Amgen INC. | $67.03 | 2022-2023 | Lumakras |
| Celgene Corporation | $59.36 | 2022 | |
| Daiichi Sankyo INC. | $53.05 | 2022-2023 | Injectafer |
| Mirati Therapeutics, INC. | $46.67 | 2023 | Krazati |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.08 | 2022-2023 | Jaypirca, Verzenio |
| Taiho Oncology, INC. | $34.29 | 2023 | |
| Merck Sharp & Dohme LLC | $30.18 | 2022-2023 | Keytruda |
| Global Blood Therapeutics, INC. | $22.12 | 2022 | |
| Shield Therapeutics INC | $21.56 | 2023 | Accrufer |
| Genentech USA, INC. | $15.03 | 2023 | Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yomi Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.